2020年免疫规划图景:试点评估指标以评价全生命周期国家免疫规划的成熟度
研究通过与疫苗专家协商制定标准化指标,选取五种疫苗(DTP、MCV第二剂、HPV最终剂、PCV最终剂、季节性流感年剂),从法律授权、规划经验和疫苗使用三方面评分,每疫苗最高5分,总分25分。分析194个WHO成员国发现,儿童疫苗规划成熟度评分最高,HPV和流感规划评分较低,全球全生命周期成熟度评分中位数为12(IQR:8;16)。该指标可为COVID-19疫苗引入前的免疫规划成熟度提供基线。
要点
- 儿童疫苗(DTP、MCV、PCV)规划成熟度评分最高,流感和HPV规划评分较低。
- 全球全生命周期成熟度评分范围为1至23,中位数为12(IQR:8;16)。
- 该试点指标结构灵活、快速,可用于评估其他疫苗组合的全生命周期规划成熟度。
核心结论
- 试点的成熟度指标提供了全生命周期免疫规划成熟度的概览,可作为COVID-19疫苗引入前儿童、青少年和成人免疫规划成熟度的基线。
- 该成熟度评分或其调整方法可用于未来监测国家全生命周期免疫规划成熟度的轨迹。
研究设计与样本
- 通过咨询疫苗专家制定标准化方法,评估全生命周期国家免疫规划成熟度。
- 选取五种疫苗代表全生命周期接种:DTP、MCV第二剂、HPV最终剂、PCV最终剂和季节性流感年剂。
- 专家推荐每种疫苗纳入以下指标:法律授权(国家政策)、接种经验(规划持续时间)和疫苗使用(相关人群接种率)。
- 指标为每种疫苗提供最高5分的「疫苗特异性成熟度评分」,总和构成「全生命周期成熟度评分」,最高25分。
- 分析194个WHO成员国的国家政策、经验和使用的流行率,按区域和世界银行收入组分层。
主要发现
- 194个WHO成员国中,超过55%的国家对DTP、MCV和PCV三种儿童疫苗均有国家政策,而HPV(青少年接种规划代理指标)为60%,季节性流感(成人接种规划代理指标)为52%。
- 儿童疫苗接种规划(如MCV和DTP)的疫苗特异性成熟度评分最高,而季节性流感和HPV接种规划评分低得多。
- 国家全生命周期成熟度评分范围为1至23,全球中位数为12(IQR:8;16)。
关键数值与推荐
- 每种疫苗的疫苗特异性成熟度评分最高5分,全生命周期成熟度评分最高25分。
- 儿童疫苗(DTP、MCV、PCV)国家政策覆盖率超过55%,HPV为60%,季节性流感为52%。
- 全生命周期成熟度评分范围为1至23,全球中位数12(IQR:8;16)。
临床怎么用
- 该试点指标可用于评估其他疫苗组合的全生命周期免疫规划成熟度。
- 该成熟度评分或其调整方法可用于监测未来国家全生命周期免疫规划成熟度的轨迹。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) encourages countries to provide appropriate vaccinations for children, adolescents, and relevant adult populations. Childhood programme have been the focus of global investments, but recent pandemics have increasingly demonstrated the value of life course vaccination. Our objective is to compare national life course immunization programmatic maturity prior to mass COVID-19 vaccine introduction, the largest adult vaccination programme, globally. As coverage estimates (typically used to assess childhood programmes) are not available for adult vaccinations, this analysis pilots a standardized quantitative metric of programmatic maturity. METHODS: Through consultation with vaccination experts, we developed a standardized approach to assess national immunization programme maturity across the life course. In accordance with expert input, five vaccines were selected to represent delivery across the life course: diphtheria tetanus toxoid and pertussis (DTP); measles (MCV) second dose; human papillomavirus (HPV) final dose; pneumococcal conjugate (PCV) final dose; and seasonal influenza annual dose. Experts recommended inclusion of the following indicators for each vaccine: a legal mandate (national policy), experience delivering the vaccine (programme duration), and vaccine use (uptake for relevant populations). We developed a metric accordingly that provides up to 5 points per vaccine ("vaccine specific maturity score") which when summed forms the "life course maturity score", with a maximum score of 25. We analysed the prevalence of national policies, experience, and use by region and World Bank income group. RESULTS: More than 55% of the 194 WHO Member States had childhood vaccine policies for all three of the vaccines considered (DTP, MCV, and PCV) compared to 60% for HPV (proxy for adolescent vaccination programme) and 52% for seasonal influenza (proxy for adult vaccination programme). Childhood vaccination programmes (e.g., MCV and DTP) had the highest vaccine specific maturity scores, while seasonal influenza and HPV vaccination programmes had much lower scores. The national life course maturity scores ranged from 1 to 23, with a global median of 12 (IQR: 8; 16). DISCUSSION: The piloted metric provides an overview of the maturity of life course immunization programmes. The metric is structured to be a flexible, rapid resource that can be used to assess other combinations of vaccines across the life course. The findings from this paper provide a baseline of immunization programme maturity for childhood, adolescent, and adult vaccination programmes immediately prior to the COVID-19 vaccine introduction. This maturity score, or adaptations of this approach, could be used to monitor the trajectory of national immunization programme maturity across the life course in the years ahead.
引用
- Goldin S, Moen A, Moss WJ, et al. The 2020 immunization programme landscape: Piloting an assessment metric to evaluate the maturity of national immunization programmes across the life course. Vaccine. 2024. PMID: 38212202. doi:10.1016/j.vaccine.2023.12.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。